CD274 and Familial prostate cancer: Anti‐programmed cell death protein 1 (PD‐1) and anti‐programmed cell death 1 ligand 1 (PD‐L1) therapy is another potential immunotherapy option for prostate cancer patients and has been confirmed to offer benefits to patients with melanoma, nonsmall cell lung cancer, breast cancer, and urothelial carcinoma.